Income statement
USD
Annual
| Metric | 2013 |
|---|---|
| Revenue | 5K |
| Gross Profit | 3K |
| Operating Income | -2K |
| EBITDA | -3M |
| Net Income | -6K |
| EPS (Diluted) | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pharmagen, Inc. (PHRX) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin -44.9% and ROIC 73.0%. Valuation is more restrained than many high-expectation growth names at price/sales 1.1. Stock Foundry combines PHRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PHRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PHRX Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PHRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.8K
FY Net Income
-$6.5K
Free Cash Flow
-$748.8
Revenue Growth
+0.0%
EPS Growth
+0.0%
Gross Margin
63.3%
Net Margin
-134.2%
Income statement
USD
| Metric | 2013 |
|---|---|
| Revenue | 5K |
| Gross Profit | 3K |
| Operating Income | -2K |
| EBITDA | -3M |
| Net Income | -6K |
| EPS (Diluted) | — |
Balance sheet
USD
| Metric | 2013 |
|---|---|
| Cash & Equivalents | 226 |
| Total Assets | 1K |
| Total Liabilities | 9K |
| Shareholder Equity | -8K |
| Total Debt | 5K |
| Net Debt | 4K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
692
Capital Expenditures
57
Free Cash Flow
749
Key ratios
Gross Margin
63.3%
Operating Margin
-44.9%
Net Margin
-134.2%
ROE
85.1%
Debt / Equity
-0.60x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.